FDA accepts Icagen's submission for senicapoc as potential asthma treatment

January 08, 2008: 10:22 AM EST

BOSTON, Jan. 8, 2008 (Thomson Financial delivered by Newstex) -- Icagen Inc. (NASDAQ:ICGN) Tuesday said the Food and Drug Administration has accepted its investigational new drug submission for senicapoc as a potential treatment for asthma.

Icagen said its submission was supported by data linking KCa3.1 to immune cell activation and cellular proliferation and efficacy data from a recently completed study. That study demonstrated the ability of senicapoc to reverse the antigen-induced changes in late phase airway resistance and airway hyper-reactivity in a sheep model of asthma.

The company expects dosing of subjects in a Phase Ib clinical trial of senicapoc to begin in January.

Shares of the Durham, N.C.-based biopharmaceutical company fell 3 cents to $1.67 on heavely volume of 61,998. The issue's 30-day average volume is 58,438 shares.

Casey Logan
Copyright Thomson Financial News Limited 2007. All rights reserved.

The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.

Newstex ID: AFX-0013-22106209